Publication:
Outcomes of Fecal Carriage of Extended-spectrum beta-Lactamase After Transrectal Ultrasound-guided Biopsy of the Prostate

Simple item page
dc.contributor.authorERTÜRK ŞENGEL, BUKET
dc.contributor.authorsTigen, Elif Tukenmez; Tandogdu, Zafer; Ergonul, Onder; Altinkanat, Gulsen; Gunaydin, Bilal; Ozgen, Mahir; Sariguzel, Nevin; Sengel, Buket Erturk; Odabasi, Zekaver; Cek, Mete; Tokuc, Resit; Turkeri, Levent; Mulazimoglu, Lutfiye; Korten, Volkan
dc.date.accessioned2022-03-13T12:46:48Z
dc.date.available2022-03-13T12:46:48Z
dc.date.issued2014
dc.description.abstractOBJECTIVE To determine the prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (PE) fecal carriage in patients that undergo transrectal ultrasonography-guided biopsy (TRUSbx) and its relationship with post-biopsy infections. METHODS A prospective clinical study in 4 different tertiary hospitals between 2008 and 2010 was conducted. Four hundred men with sterile urine who were to undergo a TRUSbx because of the suspicion of prostate cancer were included and followed for 14 days after biopsy. Rectal swab culture specimens were acquired immediately before the procedure. Demographic data, prophylaxis choice, quinolone or any other antibiotic consumption within the past 2 months, history of prostatitis, repeat biopsy, intensive care unit admission, hospitalization, urethral catheterization, diabetes mellitus (DM), and steroid usage were recorded. RESULTS ESBL carriage was detected in 19% of patients and quinolone use within the last 2 months; other antibiotic use within the last 2 months and DM were found to be significantly associated (P < .05). Symptomatic urinary tract infection (UTI) on the third day after biopsy was seen in 9% of patients and was associated with fluoroquinolone (FQ) consumption before biopsy. Although ESBL-PE carriage was associated with post-biopsy UTI symptoms, it was not found to be associated with post-biopsy symptomatic UTI. Urosepsis was seen in 2 patients (0.5%) after biopsy, and both the patients were ESBL-PE carriers. CONCLUSION The presence of ESBL-PE was associated with DM and FQ consumption before biopsy. ESBL-PE carriage was associated with a high rate of post-biopsy UTI symptoms requiring further elucidation; however, it was not associated with microbiologically proven infections. FQ consumption before TRUSbx was also associated with post-biopsy infections. (C) 2014 Elsevier Inc.
dc.identifier.doi10.1016/j.urology.2014.04.060
dc.identifier.eissn1527-9995
dc.identifier.issn0090-4295
dc.identifier.urihttps://hdl.handle.net/11424/237981
dc.identifier.wosWOS:000344478700011
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofUROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectESCHERICHIA-COLI
dc.subjectANTIBIOTIC-PROPHYLAXIS
dc.subjectRISK-FACTORS
dc.subjectINFECTIOUS COMPLICATIONS
dc.subjectCORE BIOPSIES
dc.subjectPREVALENCE
dc.subjectENTEROBACTERIACEAE
dc.subjectCOLONIZATION
dc.subjectCOMMUNITY
dc.subjectIMPACT
dc.titleOutcomes of Fecal Carriage of Extended-spectrum beta-Lactamase After Transrectal Ultrasound-guided Biopsy of the Prostate
dc.typearticle
dspace.entity.typePublication
local.avesis.id40faca76-aa1d-4cc3-9325-048d38e2060b
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages7
oaire.citation.endPage1014
oaire.citation.issue5
oaire.citation.startPage1008
oaire.citation.titleUROLOGY
oaire.citation.volume84
relation.isAuthorOfPublication67d5b9df-08b7-4c37-b042-45ea89a4c23d
relation.isAuthorOfPublication.latestForDiscovery67d5b9df-08b7-4c37-b042-45ea89a4c23d

Files

Collections

Research Outputs